Navigation Links
Misonix Reports Financial Results for First Half of Fiscal 2013
Date:2/7/2013

months ended December 31, 2012.

For the six months, royalty income received predominantly from Covidien increased 128% to $714,000.

Gross margin for the six months ended December 31, 2012 was 56.9%, primarily attributable to an unfavorable mix of low and high margin product deliveries in addition to the $360,000 amount due to Puricore International Limited under the terms of our contract. Operating expenses for the six month period increased 13% as the Company continued to invest in expanding its sales, marketing and customer support capabilities.

For the six months of fiscal year 2013, the Company reported a net loss of $(609,000), or $(0.09) per diluted share, compared to net income of $136,000, or $0.02 per diluted share, in the six months of fiscal 2012, which included income from discontinued operations ofr $712,000 for the sale of the Company's Laboratory and Forensic Safety Products Business in October 2011.

Michael A. McManus Jr., President and Chief Executive Officer of Misonix, commented, "Top-line results for the first half of fiscal 2013 are solid. Revenue for the six months increased 19%. We are particularly pleased with the 31% increase in international revenue for the first half of the year. We achieved strong revenue growth across our major product lines including BoneScalpel revenue that increased 99% and SonicOne revenue that increased 82%. Sales of our SonaStar product in the first half of 2013 were comparable to those of the same period last year. We are very pleased with the continuing acceptance by the surgical community worldwide of our BoneScalpel and SonicOne products. There were four abstracts submitted on the clinical benefits of using the BoneScalpel in spine surgery and three abstracts with regards to the benefits of utilizing our SonicOne product for wound healing during the first half and second fiscal quarter of 2013 respectively. On a cumulative basis, if we exclude declining revenue from our legacy produ
'/>"/>

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Misonix Presents at MicroCapClub Invitational
2. Misonix Terminates Distribution Agreement With Aesculap
3. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
4. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
5. Misonix Product Featured At Neurosurgery Congress
6. Misonix Adds 6 Spine Sales Agencies In The U.S.
7. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
8. Misonix Inks New Distribution Agreement For Croatia And Slovenia
9. Misonix And Soelim Create New Distribution Alliance For South Korea
10. Misonix Participates In Cleveland Spine Review
11. Misonix Adds Industry Veteran To Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or ... Todd Martensen has been ... role of Chief Commercial Officer, to oversee KLOX,s commercial ... gel for the treatment of chronic and other hard-to-heal ... approved in Europe . Mr. Martensen, ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
(Date:11/21/2014)... 2014   Coqui RadioPharmaceuticals Corp. , a medical ... producer of Molybdenum-99 (Mo-99), is proud to announce it ... to design its Medical Isotope Production Facility (MIPF) in ... parent isotope of Technetium-99, which is used in 80 ... passed legislation making it a national priority to produce ...
Breaking Medicine Technology:KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... In Children,s DNA, a Hint of a Mutation,s Ancestral ... researchers,seeking to replicate another group,s discovery of an important ... a particular,variant in DNA that may be more helpful ... populations worldwide. The finding suggests that,the gene variant, identified ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced ... clinical study of ANX-510, CoFactor(R), for the treatment ... at the 2008,American Society of Clinical Oncology (ASCO) ... 3, 2008 in Chicago, IL., The poster ...
Cached Medicine Technology:Gene Hunters Fine-Tune Marker for Common Obesity Gene 2Gene Hunters Fine-Tune Marker for Common Obesity Gene 3ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 2ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) 3
(Date:11/22/2014)... UWDress.com is gratified to introduce its new collection of ... company has also offered an attracting discount on these ... of wedding dresses, UWDress.com is good at manufacturing all ... gowns are provided over 20 colors, which have diverse ... famous for high quality. Therefore, its sales increased quickly ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Sandbridge ... equity investments in the consumer brand sector, acquired ... investment will be used to help fund BackJoy’s ... pipeline rollout, particularly its proprietary apparel and footwear ... join BackJoy’s Board of Directors. , BackJoy is ...
(Date:11/22/2014)... 2014 “Greenfield Naturals” was featured on ... , which features the latest and coolest technology products ... reporter for NewsWatch, conducted the product review and shared ... of your water. , From pollution to hazardous substances ... everything is done to remove these chemicals, especially in ...
(Date:11/22/2014)... -- A clinical trial of hydroxyurea therapy for children ... early because the results show it is a safe ... the risk of stroke. The announcement about the ... the United States and Canada, was made this week ... (NHLBI). Researchers compared monthly blood transfusions with daily ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... better when patients are treated in an ambulance by a ... researchers report. The sooner patients get the clot dissolver ... after a stroke, the researchers noted. For the best outcome, ... after stroke symptoms start, the researchers said. "The so-called ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... Simon Fraser University, has made a discovery that will change ... treated. The journal Nature has just ... and mutational evolution spectrum of primary triple negative breast cancers. ... what were thought to be triple negative breast cancer tumours. ...
... red wine, grapes and other fruits, and similar in structure ... fat cells to develop, opening a door to a potential ... Kee-Hong Kim, an assistant professor of food science, and ... in this week,s issue of the Journal of Biological ...
... April 4 (HealthDay News) -- Large amounts of lifetime ... result in post-traumatic stress disorder -- boosts inflammation levels ... The findings are important because it,s known that heart ... fare worse, according to the researchers at the University ...
... By Steven Reinberg HealthDay Reporter , ... vaccine appears to lengthen the lives of patients with ... of a small phase 2 trial. The drug, ... non-small cell lung cancer and increased the five-year survival ...
... patients with non-small cell lung cancer for both mutations and ... to predict response to treatment with antifolates, according to the ... Annual Meeting 2012, held here March 31 - April 4. ... gene mutations have a worse prognosis and do not respond ...
... CHICAGO, IL (April 4, 2012)When combined with other treatments, ... growth of cancer cellshas been shown to extend survival ... Unfortunately, about 40 percent of colorectal cancer patientsspecifically ... called KRASdo not respond to the drug. Researchers ...
Cached Medicine News:Health News:Scientists uncover multiple faces of deadly breast cancer 2Health News:Red wine, fruit compound could help block fat cell formation 2Health News:Witnessing, Experiencing Traumatic Events May Worsen Heart Disease 2Health News:Early Study Finds Some Promise for Lung Cancer Vaccine 2Health News:KRAS gene mutation and amplification status affects sensitivity to antifolate therapy 2Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2
... Immunosimplicity (Is) Rubella IgG Test Kit ... qualitative and quantitative detection of antibodies ... performed either manually or in conjunction ... The results are reported in IU/ml,which ...
... VITROS HBsAg assay is the ... the U.S. Food and Drug,Administration ... a random,access format on the ... Now you can run an,HBsAg ...
... as a quality assurance reagent ... (IgM) antibodies to hepatitis B ... antibodies to hepatitis A virus ... antigen (HBeAg) and total antibody ...
... antibody gives positive staining of prostatic ... hyperplasia. In cases of prostatic cancer, ... give definite but weak staining or ... cells; this pattern of staining permits ...
Medicine Products: